Taysha Gene Therapies Inc (TSHA)
NASDAQ
News
Market Data
Register to chat with like-minded investors on our interactive forums.
The current TSHA market cap is 440.63M. The company's latest EPS is USD -0.5444 and P/E is -3.95.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 2.4M | 4.75M | 3.6M | 3.41M | 1.11M |
| Operating Income | -23.38M | -15.63M | -15.8M | -24.33M | -21.3M |
| Net Income | -24.6M | -117.09M | 47.74M | -24.06M | -20.93M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 2.5M | 15.45M |
| Operating Income | -1.12M | -43M | -173.27M | -126.03M | -71.37M |
| Net Income | -1.12M | -60.01M | -174.52M | -166.01M | -111.57M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 81.54M | 195.77M | 172.73M | 153M | 200.39M |
| Total Liabilities | 118.66M | 244.88M | 97.79M | 99.15M | 91.53M |
| Total Equity | -37.11M | -49.11M | 74.94M | 53.85M | 108.87M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 15k | 258.88M | 213.96M | 126.28M | 172.73M |
| Total Liabilities | 150k | 7.58M | 118.57M | 125.33M | 97.79M |
| Total Equity | -135k | 251.3M | 95.38M | 949k | 74.94M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -38.95M | -56.9M | -73.02M | -19.8M | -41.3M |
| Investing | -3.85M | -7.34M | -7.35M | -140k | -341k |
| Financing | 7k | 140.64M | 136.39M | -22k | 70.45M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | N/A | -30.73M | -117.04M | -88.39M | -73.02M |
| Investing | N/A | -9.08M | -21.55M | -24.93M | -7.35M |
| Financing | N/A | 291.06M | 39.08M | 52.1M | 136.39M |
| Market Cap | 440.63M |
| Price to Earnings Ratio | -3.95 |
| Price to Sales Ratio | 28.51 |
| Price to Cash Ratio | 3.06 |
| Price to Book Ratio | 5.88 |
| Dividend Yield | - |
| Shares Outstanding | 204.94M |
| Average Volume (1 week) | 2.31M |
| Average Volume (1 Month) | 1.48M |
| 52 Week Change | -24.56% |
| 52 Week High | 4.32 |
| 52 Week Low | 1.27 |
| Spread (Intraday) | 0.13 (5.8%) |
| Company Name | Taysha Gene Therapies Inc |
| Address |
108 lakeland ave dover, delaware 19901 |
| Website | https://www.tayshagtx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
